The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Abstract
BACKGROUND: Duchenne muscular dystrophy is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment. OBJECTIVES: The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group specialised register (October 2003) using the term 'Duchenne muscular dystrophy'. We also searched MEDLINE (January 1966 to October 2003), EMBASE (January 1980 to October 2003), CINAHL and LILACS (January 1982 to October 2003). We wrote to authors of published studies and other experts in this disease to help identify other trials, checked the references in the identified trials and handsearched the abstracts of relevant journals. SELECTION CRITERIA: Types of studies: randomised or quasi-randomised trials. TYPES OF PARTICIPANTS: all patients with a definite diagnosis of Duchenne muscular dystrophy. Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months. PRIMARY OUTCOME MEASURE: prolongation of walking (independent walking without long leg calipers). SECONDARY OUTCOME MEASURES: strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures and adverse events. DATA COLLECTION AND ANALYSIS: We identified five randomised controlled trials that met the inclusion criteria for our review. Two reviewers independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double-checked. PRIMARY OUTCOME MEASURE: data from one small study used prolongation of walking as an outcome measure and did not show significant benefit. SECONDARY OUTCOME MEASURES: The meta-analysis of the results from three randomised controlled trials showed that glucocorticoid corticosteroids improved muscle strength and function over six months. Improvements were seen in time taken to rise from the floor (Gowers' time), nine metres walking time, four-stair climbing time, ability to lift weights, leg function grade and forced vital capacity. One randomised controlled trial showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to two years. The most effective prednisolone regime appears to be 0.75 mg/kg/day. Not enough data were available to compare efficacy of prednisone with deflazacort.Adverse effects: Excessive weight gain, behavioural abnormalities, cushingoid appearance and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long-term adverse effects of glucocorticoid therapy could not be evaluated because of the short-term duration of the randomised studies.Non-randomised studies: a number of non-randomised studies with important efficacy and adverse effects data are tabulated and discussed. REVIEWERS' CONCLUSIONS: There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day. In the short term, adverse effects were significantly more common but not clinically severe. Long-term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non-randomised studies support the conclusions of functional benefits but also indicate clinically significant adverse effects of long-term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 1,113
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00140-2 · Cited by 1,009
Arahata, K., & Engel, A. G. (1984) · Annals of Neurology · doi:10.1002/ana.410160206 · Cited by 630
Clinical trial in duchenne dystrophy. I. The design of the protocol
Brooke, M. H., Griggs, R. C., Mendell, J. R., Fenichel, G. M., Shumate, J. B., & Pellegrino, R. J. (1981) · Muscle & Nerve · doi:10.1002/mus.880040304 · Cited by 564
Cited by
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., & Tidball, J. G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn376 · Cited by 512
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Self-citationMcDonald, C. M., Campbell, C., Torricelli, R. E., Finkel, R. S., Flanigan, K. M., Goemans, N., Heydemann, P., Kaminska, A., Kirschner, J., Muntoni, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31611-2 · Cited by 452
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Kuntzer, T., Pike, M., & Swan, A. V. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub3 · Cited by 437
Self-citationCellular dynamics in the muscle satellite cell niche
Bentzinger, C. F., Wang, Y. X., Dumont, N. A., & Rudnicki, M. A. (2013) · The EMBO Reports · doi:10.1038/embor.2013.182 · Cited by 398
Hull, J., Aniapravan, R., Chan, E., Chatwin, M., Forton, J., Gallagher, J., Gibson, N., Gordon, J., Hughes, I., McCulloch, R., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201964 · Cited by 394
Dystrophin-Deficient Cardiomyopathy
Kamdar, F., & Garry, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.081 · Cited by 384
Biggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.01.010 · Cited by 371
Skeletal muscle regeneration is modulated by inflammation
Yang, W., & Hu, P. (2018) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2018.01.002 · Cited by 338
Yiu, E. M., & Kornberg, A. J. (2015) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12868 · Cited by 335
Contemporary Cardiac Issues in Duchenne Muscular Dystrophy
McNally, E. M., Kaltman, J. R., Benson, D. W., Canter, C. E., Cripe, L. H., Duan, D., Finder, J. D., Groh, W. J., Hoffman, E. P., Judge, D. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.015151 · Cited by 326
Duchenne and Becker Muscular Dystrophies
Flanigan, K. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.05.002 · Cited by 317
Villalta, S. A., Rinaldi, C., Deng, B., Liu, G., Fedor, B., & Tidball, J. G. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq523 · Cited by 299
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507719112 · Cited by 290
Prevalence of Duchenne and Becker Muscular Dystrophies in the United States
Romitti, P. A., Zhu, Y., Puzhankara, S., James, K. A., Nabukera, S. K., Zamba, G. K. D., Ciafaloni, E., Cunniff, C., Druschel, C. M., Mathews, K. D., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-2044 · Cited by 290
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000260974.41514.83 · Cited by 283
Moxley, R. T., Pandya, S., Ciafaloni, E., Fox, D. J., & Campbell, K. (2010) · Journal of Child Neurology · doi:10.1177/0883073810371004 · Cited by 280
Autophagy as a new therapeutic target in Duchenne muscular dystrophy
De Palma, C., Morisi, F., Cheli, S., Pambianco, S., Cappello, V, Vezzoli, M., Rovere-Querini, P., Moggio, M., Ripolone, M., Francolini, M., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.159 · Cited by 269
Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303902 · Cited by 263
Self-citationNewborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Moat, S. J., Bradley, D. M., Salmon, R., Clarke, A., & Hartley, L. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.301 · Cited by 262
Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy
Villalta, S. A., Rosenthal, W., Martinez, L., Kaur, A., Sparwasser, T., Tidball, J. G., Margeta, M., Spencer, M. J., & Bluestone, J. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009925 · Cited by 254
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Flanigan, K. M., Campbell, K., Viollet, L., Wang, W., Gomez, A. M., Walker, C. M., & Mendell, J. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.092 · Cited by 115
Skeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
Involvement of adiponectin in the pathogenesis of dystrophinopathy
Abou-Samra, M., Lecompte, S., Schakman, O., Noel, L., Many, M. C., Gailly, P., & Brichard, S. M. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0051-9 · Cited by 55
Creatine for treating muscle disorders
Kley, R. A., Vorgerd, M., & Tarnopolsky, M. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub2 · Cited by 45
AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
Abou‐Samra, M., Selvais, C. M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12531 · Cited by 44
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub3 · Cited by 38
Lecompte, S., Abou-Samra, M., Boursereau, R., Noel, L., & Brichard, S. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2465-5 · Cited by 34
Messina, S., Bitto, A., Aguennouz, M., Vita, G. L., Polito, F., Irrera, N., Altavilla, D., Marini, H., Migliorato, A., Squadrito, F., et al. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.04.014 · Cited by 33
Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
Abou-Samra, M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.02.018 · Cited by 24
Metadata
- Authors
- Manzur, A., Kuntzer, T., Pike, M., & Swan, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-04-19
- Issue
- 1
- Pages
- CD003725-CD003725
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1888941810
- Cited by
- 539
- References
- 92
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.